Puma Biotechnology jumps as drug added to guideline for breast cancer treatment

Puma Biotechnology

12/01/2022 23:23

** Puma Biotechnology's shares  PBYI.O  up 16.4% at 3.05 in
after-market trading
    ** Says its drug Nerlynx has been included in two updates of
clinical practice guideline for the treatment of breast cancer
 urn:newsml:reuters.com:*:nBw31HXTYa
    ** The guideline is from National Comprehensive Cancer
Network, not-for-profit alliance of leading cancer centers 
    ** Two of seven brokerages rate the stock "buy" or higher,
one "hold" and the remaining four "sell"; their median PT is
$6.50
    ** Up to Wednesday's close, stock had fallen nearly 14% YTD

 (Reporting by Leroy Leo)
 ((Leroy.Dsouza@thomsonreuters.com;))